

James H McMahon

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7880019/james-h-mcmahon-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

2,139
citations

21
h-index

45
g-index

80
ext. papers

2,826
ext. citations

8.1
avg, IF

4.6
L-index

#	Paper	IF	Citations
76	Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2014 , 10, e1004473	7.6	358
75	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019 , 393, 143-155	40	175
74	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. <i>Lancet HIV,the</i> , 2015 , 2, e520-9	7.8	159
73	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. <i>Science Immunology</i> , 2020 , 5,	28	134
72	Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. <i>Clinical Infectious Diseases</i> , 2011 , 52, 493-506	11.6	124
71	Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1453-61	11.6	111
70	Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. <i>Bulletin of the World Health Organization</i> , 2013 , 91, 377-385E	8.2	97
69	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , 2018 , 5, e211-e220	7.8	80
68	The HIV care cascade: a systematic review of data sources, methodology and comparability. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20634	5.4	75
67	Barriers and strategies to achieve a cure for HIV. <i>Lancet HIV,the</i> , 2018 , 5, e317-e328	7.8	58
66	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , 2016 , 7, 12731	17.4	56
65	Poverty, hunger, education, and residential status impact survival in HIV. <i>AIDS and Behavior</i> , 2011 , 15, 1503-11	4.3	46
64	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021 , 2, 100208	18	46
63	Repeated assessments of food security predict CD4 change in the setting of antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 60-3	3.1	44
62	HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S280-9	11.6	44
61	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021 , 184, 2167-2182.e22	56.2	43
60	Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. <i>Aids</i> , 2018 , 32, 35-48	3.5	38

59	Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. <i>PLoS ONE</i> , 2013 , 8, e56047	3.7	32
58	Is hospital-in-the-home (HITH) treatment of bacterial endocarditis safe and effective?. <i>Scandinavian Journal of Infectious Diseases</i> , 2008 , 40, 40-3		26
57	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. <i>Lancet HIV,the</i> , 2020 , 7, e16-e26	7.8	25
56	Experiences and expectations of participants completing an HIV cure focused clinical trial. <i>Aids</i> , 2015 , 29, 248-50	3.5	24
55	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , 2017 , 4, e486-e494	7.8	21
54	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV,the</i> , 2018 , 5, e221-e230	7.8	19
53	Diverse effects of interferon alpha on the establishment and reversal of HIV latency. <i>PLoS Pathogens</i> , 2020 , 16, e1008151	7.6	18
52	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 692-702	6.1	18
51	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020 , 60, 840-851	1.7	18
50	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. <i>Aids</i> , 2019 , 33, 773-791	3.5	18
49	Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. <i>AIDS and Behavior</i> , 2013 , 17, 2253-9	4.3	15
48	90-90-90: how do we get there?. <i>Lancet HIV,the</i> , 2014 , 1, e10-1	7.8	13
47	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). <i>PLoS ONE</i> , 2019 , 14, e0226854	3.7	13
46	Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. <i>American Journal of Health-System Pharmacy</i> , 2008 , 65, 619-23	2.2	12
45	Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care. <i>PLoS ONE</i> , 2015 , 10, e0127726	3.7	12
44	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021 , 65, 103241	8.8	11
43	Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 260-267	1.6	11
42	Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. <i>Aids</i> , 2017 , 31, 1344-1346	3.5	10

41	Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: Dramatic fall from 2011 to 2015. <i>PLoS ONE</i> , 2017 , 12, e0177634	3.7	10
40	Rapid and lasting generation of B-cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 disease and convalescence		10
39	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2017 , 31, 1137-1141	3.5	9
38	Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings. <i>Journal of the International AIDS Society</i> , 2016 , 19, 20665	5.4	9
37	Yoghurt consumption and damaged colonic mucosa: a case of <i>Lactococcus lactis</i> liver abscess in an immunocompetent patient. <i>Scandinavian Journal of Infectious Diseases</i> , 2006 , 38, 739-41		7
36	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020 , 21, 616	2.8	7
35	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , 2017 , 31, 1839-1845	3.5	6
34	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 5148-5175	8.3	6
33	The Impact of the COVID-19 Pandemic on People Living with HIV in Victoria, Australia. <i>AIDS Research and Human Retroviruses</i> , 2021 , 37, 322-328	1.6	6
32	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021 , 65, 103252	8.8	5
31	An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020 , 21, 847	2.8	4
30	Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infection 2021 ,		4
29	A New Method for Estimating the Incidence of Infectious Diseases. <i>American Journal of Epidemiology</i> , 2021 , 190, 1386-1395	3.8	4
28	Routine versus Targeted Viral Load Strategy among Patients Starting Antiretroviral in Hanoi, Vietnam. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25258	5.4	3
27	Integrase-resistant HIV in an antiretroviral-naive patient in Australia. <i>Aids</i> , 2017 , 31, 598-600	3.5	3
26	Paying the price in an era of HIV treatment as prevention: a retrospective study of the cost burden of HIV treatment for people living with HIV in Victoria, Australia. <i>Sexual Health</i> , 2015 , 12, 34-8	2	3
25	Histologic, immunohistochemical, microbiological, molecular biological and ultrastructural characterization of pulmonary tularemia. <i>Pathology Research and Practice</i> , 2011 , 207, 63-6	3.4	3
24	Leveraging the advances in HIV for COVID-19. <i>Lancet, The</i> , 2020 , 396, 943-944	4.0	3

23	Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies. <i>AIDS Research and Therapy</i> , 2020 , 17, 65	3	3
22	Treatment of disseminated histoplasmosis in advanced HIV using itraconazole with increased bioavailability. <i>International Journal of STD and AIDS</i> , 2018 , 29, 1448-1450	1.4	2
21	Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014 , 26, 559-66	2.2	2
20	Bringing evidence from press release to the clinic in the era of COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 547-549	5.1	2
19	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. <i>Aids</i> , 2021 , 35, 1631-1636	3.5	2
18	The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency. <i>Frontiers in Genetics</i> , 2021 , 12, 680725	4.5	2
17	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022 , 36, 75-82	3.5	2
16	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2021 ,	5.3	2
15	Risk factors for unstructured treatment interruptions and association with survival in low to middle income countries. <i>AIDS Research and Therapy</i> , 2016 , 13, 25	3	1
14	Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings. <i>Journal of Virus Eradication</i> , 2021 , 7, 100032	2.8	1
13	Disseminated nocardiosis with adrenal abscess masquerading as metastatic adrenal cancer in an immunocompetent adult. <i>ANZ Journal of Surgery</i> , 2021 , 91, E396-E398	1	0
12	Successful treatment of disseminated Mycobacterium simiae infection in a patient with advanced HIV. <i>Aids</i> , 2021 , 35, 157-158	3.5	0
11	IgG4-related disease masquerading as a fungating groin lesion in a patient with HIV and incomplete immune reconstitution. <i>Aids</i> , 2021 , 35, 706-707	3.5	0
10	Viral, inflammatory, and reservoir characteristics of posttreatment controllers. <i>Current Opinion in HIV and AIDS</i> , 2021 , 16, 249-256	4.2	0
9	Updated Australian guidance for health care providers about "undetectable = untransmittable" for HIV. <i>Medical Journal of Australia</i> , 2021 , 215, 201-202.e1	4	0
8	Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012-19): a longitudinal cohort study. <i>Lancet HIV</i> , 2021 , 8, e623-e632	7.8	0
7	Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 855290	5.9	0
6	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity.. <i>Nature Communications</i> , 2022 , 13, 2774	17.4	0

- 5 Less frequent CD4 monitoring in virologically suppressed HIV. *Lancet HIV,the*, **2017**, 4, e233-e234 7.8
- 4 Recruiting people with HIV to an online self-management support randomised controlled trial: barriers and facilitators. *Sexual Health*, **2019**, 16, 340-347 2
- 3 Is it time for injectable antiretroviral therapy for HIV?. *Lancet, The*, **2021**, 396, 1944-1946 40
- 2 Early Outpatient Treatment of SARS-CoV-2 (COVID-19): A Comment. *American Journal of Medicine*, **2021**, 134, e220-e221 2.4
- 1 Acceptability of Injectable Antiretroviral Therapy in Australian Travelers With HIV. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2021**, 86, e13-e15 3.1